NHLBI Archives
Cell-free hemoglobin in pulmonary hypertension
Mar. 6, 2023—Cell-free hemoglobin generated by the lungs may be a therapeutic target for treating pulmonary arterial hypertension, Vanderbilt researchers found.
Diabetes drug may improve asthma
Feb. 21, 2023—New biomarker finding strengthens the case for using GLP-1R agonists to treat patients with Type 2 diabetes who also suffer from asthma.
A new view of a cholesterol carrier
Feb. 7, 2023—Vanderbilt researchers developed a novel method to measure small RNAs carried by HDL and demonstrated that these molecules circulate in greater concentrations than previously believed and are likely to contribute to communication between immune cells.
Gut microbiota and lung fibrosis
Feb. 6, 2023—Microorganisms residing in the gut influence the severity of lung fibrosis in mouse models, suggesting that modifying the gut microbiota may offer therapeutic benefit for patients.
COVID-19 battle begins in the nose
Feb. 2, 2023—A high upper airway concentration of the virus that causes COVID-19 was associated with changes in gene expression that could impact disease progression, Vanderbilt researchers discovered.
Study finds heart failure risk higher in rural areas
Jan. 25, 2023—A study co-led by Vanderbilt researchers found heart failure risk is 19% higher for adults living in rural areas of the U.S., as compared to urban areas, and 34% higher for Black men living in rural areas.
Is drinking tea good for your gut?
Jan. 19, 2023—Microbiome profiling of older Chinese adults showed that tea drinking changed the diversity and abundance of some bacteria in men but not women — effects that may contribute to a reduced risk of hypertension.
Risk score for muscular dystrophy
Nov. 22, 2022—An imaging-based risk score can identify patients with Duchenne muscular dystrophy who are at greater risk of early mortality, allowing more intensive treatment and potentially prolonging life.
Alzheimer’s risk factor and cognition
Nov. 8, 2022—Vanderbilt researchers found that a protein with roles in innate immunity worsens memory at baseline in carriers of APOE-e4, the strongest genetic risk factor for Alzheimer’s disease, further implicating neuroinflammation in cognitive decline.
Metabolic signatures of Type 2 diabetes risk
Oct. 24, 2022—Vanderbilt epidemiologists found 32 blood metabolites associated with obesity and showed that adding these to traditional disease prediction models improves accuracy of determining Type 2 diabetes risk.
New target for lung fibrosis
Oct. 20, 2022—Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.
Skin pigment affects oxygen monitor
Oct. 11, 2022—Black patients in the ICU were more likely to have low or high blood oxygen levels than white patients, even when a pulse oximeter indicated 92-96% oxygen saturation, Vanderbilt researchers found.
